The article reports that the $0.39 non-GAAP of Biogen Idec is inline with the consensus estimate as indicated by Barclays analyst Jill Birchenough in the U.S. However, due to the PML brain infection reported in European Patient following the 12-month Tysabri monotherapy, it will suffer from ...
D0TxsJLSyctKYhEhI99AdbdEFjINoeNJPelACNF+6aWXoi6Quy1btvRIR4a1WRmRZb8qD9jZOjgm jjSOsR0roiLHxGFz9AA4aVmdAyhsOGXKlHDPPffErSOsuFu7p/qJAKvdAHzatGnhyJEjsR5LZKkb Ym/1ou633347LFy4sFAv6edhe02c7i/3l2OgtTCwZt3GAHGVXxivp0ydXlvhtKSTcX/tuk3hh3/7 k/CNb34n/OSffhbe3bs/lmU+YV8s+fmPGTsxLFi0...